This investigational new drug (IND) application represents the second IND filed by the company in 2007 for MSI- 1436 (trodusquemine). MSI-1436 is a novel therapeutic acts by regulating insulin and leptin receptor signaling through inhibition of the tyrosine phosphatase, PTP-1B.
Jack Armstrong, president and CEO of Genaera, said: “Since MSI-1436 has demonstrated significant potential to impact both the insulin and leptin pathways, we believe this new IND provides us with the opportunity for additional indications and a much broader potential market. Therefore, we are implementing a clinical plan which evaluates the drug’s potential in type 2 diabetes, in addition to our ongoing obesity studies.”